Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization.
The 97.7% dividend payout ratio eliminates capital flexibility, making margin stability absolutely paramount to the thesis.
Sanofi is a mature, dividend-paying global pharmaceutical company currently trading at a steep discount to major peers (8.4x forward P/E vs peer median 14.0x). Generating robust free cash flows ($7.2B in the latest year), it supports a strong 5.55% dividend yield. While historical revenue growth is moderate, near-term estimates suggest stable low-to-mid single-digit expansion.
Sanofi is a mature, dividend-paying global pharmaceutical company currently trading at a steep discount to major peers (8.4x forward P/E vs peer median 14.0x). Generating robust free cash flows ($7.2B in the latest year), it supports a strong 5.55% dividend yield. While historical revenue growth is moderate, near-term estimates suggest stable low-to-mid single-digit expansion.
Scale in immunology, vaccines, and rare diseases
Robust absolute free cash flow generation ($7.2B)
Acceleration in immunology and rare disease commercialization, expanding operating margins.
Buy.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Top-line growth stagnates near 1% as the pipeline fails to offset competitive pressures across core segments. With the payout ratio already at 97.73%, any margin contraction creates severe risk of a dividend freeze or cut. Valuation multiple remains trapped.
Scale in immunology, vaccines, and rare diseases
Robust absolute free cash flow generation ($7.2B)
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
The highlighted base cell is anchored to composite fair-value midpoint ($51.15). It is the reference value for this grid, not a separate standalone fair-value claim.
FCFF DCF remains positive at the base case: base FCFF $9.1B after capex $4.1B, with at 56.8% of . No cliff is projected unless capex/ or materially resets.
If forward revenue growth > 4.82% and margins > 20%, market begins re-rating terminal multiple toward 12x. If margins < 20%, dividend cut fears trigger multiple compression toward 8x.
If forward revenue growth > 4.82% and margins > 20%, market begins re-rating terminal multiple toward 12x. If margins < 20%, dividend cut fears trigger multiple compression toward 8x.
Normal capex phase (7.57% of revenue). Reinvestment severely restricted by the 97.7% dividend payout structure.
Acceleration in immunology and rare disease commercialization, expanding operating margins.
Patent cliffs and generic market penetration compressing legacy pricing power.
Normal capex phase (7.57% of revenue). Reinvestment severely restricted by the 97.7% dividend payout structure.
Standard weight.
Trim exposure if the operating margin falls below 20.0%, which would critically threaten the 97.7% dividend payout structure.
Buy.
Trading at a steep discount (8.4x vs 14.0x peer median) reflecting unjustified pessimism over mature pipeline assets.
Buy.
Downside case: The 97.7% dividend payout ratio eliminates capital flexibility, making margin stability absolutely paramount to the thesis.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Top-line growth stagnates near 1% as the pipeline fails to offset competitive pressures across core segments. With the payout ratio at 97.73%, any margin contraction creates severe risk of a dividend freeze or cut, trapping the multiple at 8.0x.
Operating margin dips below the 20.00% trailing average, compressing available free cash flow.
The 97.73% payout ratio forces a dividend cut due to unexpected top-line stagnation near 1%.
Pipeline fails to offset competitive pressures across core immunology and oncology commercial segments.
The five developments that would weaken our investment case.
Sustained profitability contraction erodes cash conversion efficiency and reduces internal funding capacity needed to support extensive late-stage clinical trials, increasing dependence on external capital.
Current:Operating margin was 20.5% for the period ended 2025-12-31
Alert ifDeclines below 20.0% over any trailing twelve-month period
Top-line stagnation indicates commercial portfolio exhaustion and an inability to offset loss of exclusivity, impairing operational leverage and constraining enterprise reinvestment.
Current:Revenue growth was 5.5% for the period ended 2025-12-31
Alert ifSlows to 1.0% or lower for two consecutive fiscal years
Clinical setbacks eliminate anticipated successor revenue streams required to replace maturing legacy blockbusters, exposing the business to patent cliffs and severe volume losses.
Current:Active clinical pipeline across core immunology and oncology segments as of 2026-05-20
Alert ifFiled regulatory rejection, trial termination, or clinical suspension of a lead Phase 3 candidate within 12 months
Distributing more cash than generated forces management to divert liquidity from capital expenditures or take on debt to sustain shareholder distributions, creating imminent risk of distribution reductions.
Current:Payout ratio of 97.73% as of 2026-05-20
Alert ifExceeds 100.0% over any trailing twelve-month period
Cash generation lagging reported earnings highlights working capital absorption or aggressive revenue accruals, undermining earnings quality and reducing discretionary cash available for balance sheet flexibility.
Current:Operating cash flow to net income was 1.376 as of the report's 2026-05-20 analysis date
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at , then adjust for signed per current share.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization. Operating margins improve past 20%, and the equity partially re-rates toward the peer median.
Growth remains stable, anchored by vaccines and rare diseases. The 12.0x terminal multiple reflects a conservative partial re-rating from the current 8.4x, deliberately constrained below peers due to the rigid 97.7% dividend payout policy.
If forward revenue growth > 4.82% and margins > 20%, market begins re-rating terminal multiple toward 12x. If margins < 20%, dividend cut fears trigger multiple compression toward 8x.
If forward revenue growth > 4.82% and margins > 20%, market begins re-rating terminal multiple toward 12x. If margins < 20%, dividend cut fears trigger multiple compression toward 8x.
Warning level: Declines below 20.0% over any trailing twelve-month period. Sustained profitability contraction erodes cash conversion efficiency and reduces internal funding capacity needed to support extensive late-stage clinical trials, increasing dependence on external capital.
Warning level: Slows to 1.0% or lower for two consecutive fiscal years. Top-line stagnation indicates commercial portfolio exhaustion and an inability to offset loss of exclusivity, impairing operational leverage and constraining enterprise reinvestment.
Warning level: Filed regulatory rejection, trial termination, or clinical suspension of a lead Phase 3 candidate within 12 months. Clinical setbacks eliminate anticipated successor revenue streams required to replace maturing legacy blockbusters, exposing the business to patent cliffs and severe volume losses.
Warning level: Exceeds 100.0% over any trailing twelve-month period. Distributing more cash than generated forces management to divert liquidity from capital expenditures or take on debt to sustain shareholder distributions, creating imminent risk of distribution reductions.
Warning level: Drops below 1.0x over any four-quarter measurement period. Cash generation lagging reported earnings highlights working capital absorption or aggressive revenue accruals, undermining earnings quality and reducing discretionary cash available for balance sheet flexibility.
| $41.62B |
| $44.29B |
| $46.72B |
| +4.8% |
| Gross profit | $28.68B | $28.99B | $31.08B | $33.67B | +5.5% |
| Operating income | $10.40B | $6.89B | $7.40B | $6.80B | -13.2% |
| Net income | $8.37B | $5.40B | $5.56B | $7.81B | -2.3% |
| EPS (diluted) | $2.69 | $2.16 | $2.30 | $3.20 | +6.0% |
| EBITDA | $13.51B | $11.32B | $10.99B | $12.48B | -2.6% |
| R&D | $6.50B | $6.51B | $7.39B | $7.84B | +6.5% |
| SG&A | $8.74B | $9.48B | $9.82B | $10.24B | +5.4% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 46,716,000,000 |
|---|---|
| Cost of revenue | 13,049,000,000 |
| Gross profit | 33,667,000,000 |
| Operating expenses | 24,070,000,000 |
| Operating income | 9,597,000,000 |
| Non-operating items and tax | -1,784,000,000 |
| Net income | 7,813,000,000 |
| Total assets | 126,805,000,000 |
|---|---|
| Cash | 7,657,000,000 |
| Current assets | 30,952,000,000 |
| Total liabilities | 55,095,000,000 |
| Current liabilities | 28,345,000,000 |
| Shareholders’ equity | 71,376,000,000 |
Point-in-time financial data used in the 2026-05-20 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 40.6B | 13.5B | 8.4B | 10.5B | 8.4B | 2.1B | 3.1B | — | 497M | 4.2B | -1.2B | — | — | — | — | 12.7B | 21.2B | 26.9% | — | — | — |
| 2023-12-31 | 41.6B | 11.3B | 5.4B | 10.3B | 7.4B | 2.9B | 4.4B | — | 593M | 4.5B | -3.1B | — | — | — | — | 8.7B | 18.4B | 20.9% | — | — | — |
| 2024-12-31 | 44.3B | 11B | 5.6B | 9.1B | 5.9B | 3.2B | 3.6B | — | 302M | 4.7B | -894M | — | — | — | — | 7.4B | 17.9B | 20.1% | — | — | — |
| 2025-12-31 | 46.7B | 12.5B | 7.8B | 10.8B | 7.2B | 3.5B | 5.7B | — | 5B | 4.8B | 1.5B | — | — | — | — | 7.7B | 20.3B | 20.5% | — | — | — |
SNY trades at 8.4x forward earnings against a peer median of 14.1x; EV/EBITDA of 5.2x against a peer median of 14.5x; 6 peers.
| Level | Action |
|---|---|
| Thesis break | Trim exposure if the operating margin falls below 20.0%, which would critically threaten the 97.7% dividend payout structure. |
Alert ifDrops below 1.0x over any four-quarter measurement period
This edition does not contain enough finite inputs to reproduce the lens calculation.
| Johnson & Johnson |
| 18.1x |
| 5.7x |
| 17.1x |
| 26.4% |
| 27.4% |
| ABBV | AbbVie Inc. | 13.2x | 6.0x | 14.5x | 62.2% | 32.2% |
| MRK | Merck & Co. Inc. | 12.0x | 4.3x | 11.0x | 18.9% | 38.6% |
| AMGN | Amgen Inc. | 14.1x | 4.8x | 13.2x | 101.3% | 33.8% |
